Allorion Therapeutics is a clinical-stage biotech developing precision medicines for oncology and autoimmune diseases. Its core capabilities include an allosteric inhibitor screening platform and a platform for discovery of synthetic lethality targets and molecules. The company has advanced two small molecules to IND: ARTS-011, an allosteric TYK2 pseudokinase inhibitor with an IND filed in China for autoimmune diseases, and ARTS-021, a CDK2 isoform-selective inhibitor for solid tumors with INDs to be filed in the U.S. and China. Allorion intends to use its new funding to advance upcoming Phase I/II clinical trials in both China and the U.S., identify additional clinical candidates, and further build clinical development and business development teams. Led by CEO Peter Ding, the company has 53 full-time employees across China and the U.S., including 15 executive team members with extensive pharma/biotech experience. Since its July 2020 founding the company has raised over $100M, most recently a $50M Series B. Allorion Therapeutics is a Boston, MA-based next-generation precision medicine company focused on oncology and autoimmune diseases. The company leverages a drug discovery engine that integrates breakthroughs in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors. It has built a synthetic lethality screening platform to expand targeted therapy options for cancer patients. Allorion is developing two drug candidates with plans for IND-enabling studies and IND applications in China and the United States. It intends to increase investment in its platform technologies for systematic screens for allosteric inhibitors and synthetic lethality targets with matching tool compounds. The company also plans to enhance its clinical and business development teams and recently completed a $40M Series A financing.

Total raised

$90M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2023